GIMBHI’s daily mental health update — 05/04/26

📉 Aurora Mental Health and Recovery lays off 91+ employees amid funding challenges (Laura Lovett, Behavioral Health Business) — 05/04/26
TL;DR: Colorado-based Aurora Mental Health and Recovery will cut 91+ jobs by end of June, citing lower state and federal reimbursements, anticipated Medicaid reductions from the One Big Beautiful Bill Act, and a $7.2M Medicaid reconciliation order. Layoffs hit administrative staff, educational programs, and some clinical roles, with several programs closing entirely.

🪖 Active-duty US soldiers to receive psychedelic drugs for PTSD next year (The Guardian) — 04/30/26
TL;DR: DoD-funded studies will give MDMA-assisted therapy to 186 active-duty service members with PTSD; new DoD/VA therapists begin training next week.

🏥 Governor Hochul announces $13.7M to expand and improve NY inpatient psychiatric units (LongIsland.com) — 04/30/26
TL;DR: NY OMH awarded $13.7M to nine providers across the state to add psychiatric beds and upgrade inpatient units, building on a 1,000-bed expansion under Hochul’s mental health initiative.

🥽 Saudi Arabia-based Metafare secures $1M to scale VR and AI-driven wellness (Dr. Asawari Savant, eHealth Network) — 05/04/26
TL;DR: Metafare raised $1M led by Harmonix Ventures to scale its VR and AI hybrid wellness platform, which delivers under-15-minute sessions blending fitness, mental health, and CBT. Funds will expand its AI personalisation engine and fuel Gulf region growth after 3,000+ sessions delivered since mid-2025.

🏥 Brightline opens pediatric mental health clinic in White Plains, New York (Business Wire) — 04/30/26
TL;DR: Brightline opened its fourth New York-area clinic in White Plains to serve families across Westchester and Connecticut, addressing long waitlists and a 32% rise in youth mental health incidences. The hybrid in-person and virtual clinic offers therapy, psychiatry, and psychological testing for kids and teens up to age 18.

🧠 FDA greenlights brain implant trial for treatment-resistant depression (Mack DeGeurin, Popular Science) — 05/01/26
TL;DR: The FDA approved a human trial for Motif Neurotech’s blueberry-sized brain implant DOT, designed to deliver wireless electrical stimulation for treatment-resistant depression via a 20-minute outpatient procedure and a wearable cap. The 12-month trial will involve about 10 patients and could mark the first BCI used to treat clinical depression.

💬 Heyypal secures funding to expand on-demand mental health platform in India (BW Online Bureau, BW Healthcare World) — 04/22/26
TL;DR: Indian on-demand mental health platform Heyypal raised an undisclosed amount from Abu Dhabi-based investor Umesh Bhatt at a Rs 20 crore valuation. The funding will support expansion, platform upgrades, and growth of its therapist network to address access, affordability, and stigma barriers in India’s mental health space.

🤝 Zócalo Health raises $15M Series A to expand community-based care and Medicaid partnerships (Jasmine Pennic, HIT Consultant) — 04/23/26
TL;DR: Zócalo Health closed a $15M Series A led by EO Ventures, bringing total funding to $22.75M, to scale its “promotoras de salud” community health worker model integrating medical and behavioral health for high-need Medicaid members. The company achieved 4x revenue growth and grew from 2 to 12+ health plan partnerships, including Anthem Blue Cross and Health Net.

🎮 brainjo secures €2M seed funding for VR mental health tech (News Desk, Health Tech World) — 04/20/26
TL;DR: Regensburg-based brainjo raised €2M in seed funding led by High-Tech Gründerfonds to develop prescribable VR-based Digital Health Applications (DiGAs) that complement psychotherapy. The capital will fund a clinical study and regulatory approval for its first product targeting children with ADHD, developed with MEDICE, with market approval planned for 2028.

🧬 Axoft secures $55M Series A to advance clinical trials for bio-inspired brain-computer interface (Business Wire) — 04/29/26
TL;DR: Cambridge-based Axoft raised $55M Series A led by C.P. Group Innovation to expand global clinical trials for its implantable brain-computer interface, powered by Fleuron™ material that’s up to 10,000x softer than polyimide. The company has implanted iBCIs in 11 patients to date and will use the funds to pursue U.S. regulatory approval and build a GMP manufacturing facility.